| __timestamp | Bausch Health Companies Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 46425000 |
| Thursday, January 1, 2015 | 582800000 | 81491000 |
| Friday, January 1, 2016 | 455000000 | 94291000 |
| Sunday, January 1, 2017 | 366000000 | 121827000 |
| Monday, January 1, 2018 | 414000000 | 160524000 |
| Tuesday, January 1, 2019 | 471000000 | 200000000 |
| Wednesday, January 1, 2020 | 452000000 | 275000000 |
| Friday, January 1, 2021 | 465000000 | 328100000 |
| Saturday, January 1, 2022 | 529000000 | 463800000 |
| Sunday, January 1, 2023 | 604000000 | 565000000 |
| Monday, January 1, 2024 | 731100000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Bausch Health Companies Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Bausch Health's R&D expenses grew by approximately 145%, peaking in 2023. Meanwhile, Neurocrine Biosciences, Inc. showcased a remarkable increase of over 1100% in the same period, reflecting a strategic pivot towards aggressive innovation. By 2023, Neurocrine's R&D spending nearly matched Bausch Health's, highlighting its rapid ascent in the industry. This trend underscores the dynamic nature of pharmaceutical R&D, where strategic investments can redefine market positions. As these companies continue to innovate, their R&D strategies will be pivotal in shaping their future trajectories.
Comparing Innovation Spending: Amgen Inc. and Neurocrine Biosciences, Inc.
Research and Development: Comparing Key Metrics for argenx SE and Bausch Health Companies Inc.
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and Bausch Health Companies Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Veracyte, Inc. vs Bausch Health Companies Inc.
Research and Development Expenses Breakdown: Bausch Health Companies Inc. vs Mesoblast Limited
Analyzing R&D Budgets: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated